BioAge Labs, Inc. (BIOA)
| Market Cap | 659.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.94M |
| Shares Out | 35.85M |
| EPS (ttm) | -33.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,301 |
| Open | 19.01 |
| Previous Close | 19.17 |
| Day's Range | 18.11 - 19.18 |
| 52-Week Range | 18.00 - 26.62 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 42.33 (+130.05%) |
| Earnings Date | Nov 7, 2024 |
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for BIOA stock is "Strong Buy." The 12-month stock price forecast is $42.33, which is an increase of 130.05% from the latest price.
News
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents su...
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic dise...
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
The biotech sector is reviving, with IPOs reappearing and BioAge Labs' weight loss drug, Azelaprag, showing market potential. Biotech stocks are volatile, facing challenges like regulatory hurdles and...
U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Four IPOs and two SPACs submitted initial filings this past week. Six IPOs are currently scheduled to list in the...
BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
BioAge Labs is having its initial public offering today. The drug developer's signature product, Azelaprag, isn't yet on sale, but it is undergoing clinical trials in hopes it will one day be.
Natural-gas producer BKV and drug-developer BioAge queue up IPOs
Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead of trading.
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday.
BioAge Labs Announces Pricing of Upsized Initial Public Offering
RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic dis...
Obesity drug developer BioAge Labs targets up to $640 mln valuation in upsized US IPO
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from inv...
U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost
Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight...
U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows
Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, in...
BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment
BioAge Labs, Inc. is seeking $100 million in an IPO to fund its clinical trials for obesity and insulin sensitivity treatments. The company's lead drug, Azelaprag, is in Phase 2 trials, with promising...
Eli Lilly partner BioAge files for US IPO
BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly , filed for an initial public offering in the United States on Tuesday as it looks to capitalize on investors'...
BioAge Labs IPO Registration Document (S-1)
BioAge Labs has filed to go public with an IPO on the NASDAQ.